… This study uses real-world evidence to assess voxelotor’s effectiveness in SCD patients in
typical clinical practice from 2019 to 2021 using a national medical claims database (N = 3128…

… ‐dose study to evaluate the pharmacokinetics, efficacy, and safety of voxelotor—a first‐in‐class …
Initial findings from a cohort of 45 patients aged 4 to 11 years who received voxelotor …

… sufficient evidence of the safety and efficacy of voxelotor in increasing hemoglobin
concentration and decreasing hemolysis in patients with sickle cell disease ages 12 and older. A …

… , we compared the efficacy and safety of two dose levels of voxelotor (1500 mg and 900 mg,
administered orally once daily) with placebo in persons with sickle cell disease. The primary …

… to assess safety and establish preliminary efficacy of voxelotor. Efficacy was evaluated in the
… randomized to receive 28 days of voxelotor 500 mg/d (n = 10), voxelotor 700 mg/d (n = 12), …

… demonstrated that treatment with voxelotor 1500 mg resulted in … the evaluation of efficacy
and safety of voxelotor 1500 mg at … the evaluation of efficacy and safety of voxelotor 1500 mg at …

… the real-world effectiveness of voxelotor based on data … ≥12 years and receiving voxelotor
from December 2019 to May … the real-world effectiveness of voxelotor based on data during …

… provides the largest single-institution cohort analysis of patients with SCD treated with
voxelotor and provides helpful insight for patients and clinicians regarding real-world efficacy. …

… Voxelotor (GBT440) is a hemoglobin modulator that prevents … evaluate the efficacy and safety
of voxelotor in SCD patients. … to evaluate the efficacy and safety of voxelotor in SCD patients…

… , however, understanding the effectiveness and tolerability of these medicaments will … of
voxelotor, l-glutamine, and crizanlizumab on SCD patients, specifically their response, efficacy, …